~ Nov 08 Detect Your Risk of Sudden Heart Attack and Stroke References

References

1. Available at: http://www.webmd.com/heart-disease/news/20080616/tim-russerts-death-questions-answers. Accessed June 16, 2008.

2. Weintraub HS. Identifying the vulnerable patient with rupture-prone plaque. Am J Cardiol. 2008 Jun 16;101(12A):3F-10F.

3. Wilensky RL, Hamamdzic D. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Curr Opin Cardiol. 2007 Nov;22(6):545-51.

4. Naghavi M, Falk E, Hecht HS, Shah PK. The First SHAPE (Screening for Heart Attack Prevention and Education) Guideline. Crit Pathw Cardiol. 2006 Dec;5(4):187-90.

5. Clarke J. Heart disease and gender in mass print media. Menopause Int. 2008 Mar;14(1):18-20.

6. Lavi S, McConnell JP, Rihal CS, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007 May 29;115(21):2715-21.

7. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008 Jun 16;101(12A):51F-7F.

8. Adibhatla RM, Dempsy R, Hatcher JF. Integration of cytokine biology and lipid metabolism in stroke. Front Biosci. 2008;13:1250-70.

9. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2523-9.

10. Mannheim D, Herrmann J, Versari D, et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke. 2008 May;39(5):1448-55.

11. Lerman A, McConnell JP. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am J Cardiol. 2008 Jun 16;101(12A):11F-22F.

12. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008 Jun 16;101(12A):23F-33F.

13. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16;101(12A):41F-50F.

14. Yang EH, McConnell JP, Lennon RJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):106-11.

15. Daniels LB, Laughlin GA, Sarno MJ, et al. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol. 2008 Mar 4;51(9):913-9.

16. Gorelick PB. Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol. 2008 Jun 16;101(12A):34F-40F.

17. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med. 2004 May 30;23(10):1631-60.

18. Raichlin E, McConnell JP, Bae JH, et al. Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. Transplantation. 2008 Apr 15;85(7):963-8.

19. Rosenson RS. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J. 2008 Mar;155(3):499.

20. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2007 Aug;193(2):428-37.

21. Schmidt EB, Koenig W, Khuseyinova N, Christensen JH. Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis. 2008 Jan;196(1):420-4.

22. Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006 Sep 15;98(6):743-5.

23. Chethankumar M, Srinivas L. New biological activity against phospholipase A2 by Turmerin, a protein from Curcuma longa L. Biol Chem. 2008 Mar;389(3):299-303.

24. Kao WT, Yen YC, Lung FW. The effects of beta2 adrenergic receptor gene polymorphism in lipid profiles. Lipids Health Dis. 2008;720.

25. Mockel M, Danne O, Muller R, et al. Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Clin Chim Acta. 2008 Jul;393(2):103-9.

26. Khush KK, Waters D. Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients. Cleve Clin J Med. 2004 Aug;71(8):609-16.

27. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1172-8.

28. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005 Nov 28;165(21):2479-84.

29. Brilakis ES, Khera A, McGuire DK, et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis. 2008 Jul;199(1):110-5.

30. El-Saed A, Sekikawa A, Zaky RW, et al. Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men. J Epidemiol. 2007 Nov;17(6):179-85.


Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.